US FDA approves expanded use of AstraZeneca cancer drug

  • US FDA approves expanded use of AstraZeneca cancer drug

US FDA approves expanded use of AstraZeneca cancer drug

Doctors had found that the star had mutations in BRCA genes which increase a woman's risk of breast cancer by four-to-eightfold.

Fiona MacNeill, of the Royal Marsden NHS Foundation Trust, who was not involved in the research, said: "This study can reassure young women with breast cancer, particularly those with triple negative cancer or who are BRCA carriers, that breast conservation with radiotherapy is a safe option in the first decade after diagnosis and double mastectomy is not essential or mandatory at initial treatment. Any relationship will have a major health impact", Øjvind Lidegaard, MD, DMSc, of the University of Copenhagen in Denmark, told Cancer Therapy Advisor.

The study, published in The Lancet Oncology, found 12% of 2,733 women aged 18 to 40 treated for breast cancer at 127 hospitals across the United Kingdom between 2000 and 2008 had a BRCA mutation. Findings from epidemiologic studies have, however, been mixed, with only some data sets showing an association between hormonal contraceptive use and oncogenesis.

The women, who were recruited between 2000 and 2008, were monitored for an average of 8.2 years to discover more about their treatment, whether their cancer returned, or if they died.

BRCA mutations can cause cancer because the DNA self-repair mechanisms can malfunction.

Most of the women lived 10 years; 73 percent of the women with BRCA mutations lived 10 years and 70 percent of women without the mutations did.

Few studies have looked at whether these genes are linked with lower survival in young breast cancer patients, which this research aimed to address.

Today, the FDA approved olaparib tablets (Lynparza) for the treatment of patients with metastatic breast cancer whose tumors have a germline genetic mutation, according to a press release.

The study's author, Professor Diana Eccles, of the University of Southampton, said: "Women diagnosed with early breast cancer who carry a BRCA mutation are often offered double mastectomies soon after their diagnosis or chemotherapy treatment".

The researchers tracked the women a their treatment for more than eight years.

A faulty gene famously carried by Angelina Jolie does not make young women less likely to survive breast cancer, researchers have found.

Some 89 per cent underwent chemotherapy. It means that they can take time to discuss whether radical breast surgery is the right choice for them as part of a longer-term risk-reducing strategy.

"Decisions about timing of additional surgery to reduce future cancer risks should take into account patient prognosis after their first cancer, and their personal preferences", she added. Half had breast-conserving surgery, half had a full mastectomy and less than 1 per cent had no breast surgery. Roughly 30 to 60 percent of BRCA1 or BRCA2 carriers will develop breast cancer in their lifetime, compared to an estimated 12 percent of women in the general population.